RFA-HL-24-006: Molecular Atlas of Lung Development Program (LungMAP) Phase 3 - Research Centers (U01 Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2023.
National Institutes of Health offered grants of up to $500,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on October 27, 2023.
From the official notice on Grants.gov, last changed July 14, 2023. Checked November 7, 2026.
- Award ceiling$500,000
- Cost sharingNot required
- Funding typeCooperative Agreement
About this NIH notice
- Activity codeU01
- Clinical trialsNot allowed
- Funded byNHLBI
- Median yearly award$790,713
- Typical project length5 years
- U01, Research Project Cooperative Agreement. Like an R01, but NIH staff are substantially involved in the work. Other open U01 notices.
Projects funded under RFA-HL-24-006 were run by National Heart Lung and Blood Institute (NHLBI, 6 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-HL-24-006 in the NIH Guide.
Key dates
| Posted | July 14, 2023 |
|---|---|
| Deadline | October 27, 2023 |
| Archived by Grants.gov | December 2, 2023 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $790,713; it allows up to $500,000 per award.
- Most of the program's money (59% over five years) went to nonprofits.
- No cost sharing or match is required.
What the grant funds
The purpose of this NOFO is to support the Molecular Atlas of Lung Development Program (LungMAP) Phase 3 Research Centers (RCs). The overall goal of LungMAP is to build a comprehensive molecular and cellular atlas of the human lung to serve as a reference platform to better understand both normal biology and disease pathobiology, and to identify critical cellular components, molecular pathways, and novel therapeutic targets in lung disease. RCs will be expected to obtain and analyze pediatric and adult lung tissues in order to generate high-resolution molecular profiling data of the diseased lung. RCs will perform integrated data analysis, explore mechanisms of disease pathogenesis, collaborate closely with other LungMAP teams and to disseminate this resource to the broader research community. Applicants are not required to have been funded in LungMAP Phase 2 (RFA-HL-19-020) in order to submit applications to this NOFO.
Funded under RFA-HL-24-006 so far
NIH funded 6 projects under RFA-HL-24-006 in fiscal 2024 to 2026, at 6 institutions. The median yearly award was $790,713.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| A mechanistic 3D AI-powered map of genetic chILD | Cincinnati Childrens Hosp Med Ctr | 2026 | $786,450 |
| Cross-Disease Multi-Modality Mapping of the Human Lung | University of California, San Diego | 2026 | $727,022 |
| The Penn LungMAP 3 team: Defining chronic lung disease | University of Pennsylvania | 2026 | $744,194 |
| Mapping Airway Epithelial Cell-Immune Cell Interactions in Lung Health and Disease | Massachusetts General Hospital | 2026 | $765,687 |
| Unraveling the molecular origins of chronic parenchymal lung diseases | Vanderbilt University Medical Center | 2026 | $893,029 |
| Cell-cell and cell-matrix interactions driving progressive fibrosis in interstitial lung diseases | University of California Los Angeles | 2026 | $779,780 |
Who has won Lung Diseases Research grants before
From fiscal 2021 to 2025, Lung Diseases Research (93.838) awarded $8.7 million across 5 grant awards, an average of $1.7 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The General Hospital Corporation | Massachusetts | 1 | $5.4 million |
| New England Research Institutes Inc | Massachusetts | 1 | $2.7 million |
| The Trustees of the University of Pennsylvania | Pennsylvania | 1 | $355,699 |
| University of Washington | Washington | 1 | $350,272 |
| The Trustees of Columbia University in the City of New York | New York | 1 | $319,659 |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-HL-24-006 still open?
No. It closed on October 27, 2023.
Who can apply for Molecular Atlas of Lung Development Program (LungMAP) Phase 3 - Research Centers (U01 Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Molecular Atlas of Lung Development Program (LungMAP) Phase 3 - Research Centers (U01 Clinical Trial Not Allowed)?
Closed October 27, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $500,000 each.
Who has been funded under RFA-HL-24-006?
NIH RePORTER lists 6 projects funded under RFA-HL-24-006 in fiscal 2024 to 2026, at 6 institutions. The most were at Cincinnati Childrens Hosp Med Ctr, University of California, San Diego, University of Pennsylvania.
Who has won Lung Diseases Research grants before?
The largest recipients over five fiscal years were The General Hospital Corporation, New England Research Institutes Inc, The Trustees of the University of Pennsylvania. The program made 5 awards worth $8.7 million in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Single Source for the Continuation of the Physiology of the Weight Reduced State (POWERS) Study (U01- Clinical Trials Required)
- Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed)
- Opportunities for Collaborative Research with the NIH Intramural Research Program (U01 Clinical Trial Optional)